Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)‐b‐poly(dl‐lactic acid) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine
- 1 October 2012
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 101 (10) , 3787-3798
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessmentInternational Journal of Nanomedicine, 2011
- A Novel Preparation Method for Camptothecin (CPT) Loaded Folic Acid Conjugated Dextran Tumor-Targeted NanoparticlesInternational Journal of Molecular Sciences, 2011
- Recent advances in PEG–PLA block copolymer nanoparticlesInternational Journal of Nanomedicine, 2010
- Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyJournal of Clinical Oncology, 2010
- Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivoMolecular Cancer, 2010
- Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugsJournal of Controlled Release, 2009
- Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular ArchitectureAccounts of Chemical Research, 2009
- In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitorsInternational Journal of Pharmaceutics, 2008
- Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in ratsJournal of Controlled Release, 2008
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007